Intravascular Large B-Cell Lymphoma Genomic Profile Is Characterized by Alterations in Genes Regulating NF-κB and Immune Checkpoints
Authors:
- Blanca Gonzalez-FarreBGBlanca Gonzalez-Farre
- Joan E. Ramis-ZaldivarJRJoan E. Ramis-Zaldivar
- Natalia Castrejón de AntaNANatalia Castrejón de Anta
- Alfredo Rivas-DelgadoARAlfredo Rivas-Delgado
- Ferran NadeuFNFerran Nadeu
- Julia Bs Salmeron-VillalobosJSJulia Bs Salmeron-Villalobos
- Anna EnjuanesAEAnna Enjuanes
- Kennosuke KarubeKKKennosuke Karube
- Olga BalaguéOBOlga Balagué
- Francesc CoboFCFrancesc Cobo
- Nicholas KelleherNKNicholas Kelleher
- Ingrid Bs VictoriaIVIngrid Bs Victoria
Open Access
- 12 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 47 (2) , 202-211
Abstract
Intravascular large B-cell lymphoma (IVLBCL) is an uncommon lymphoma with an aggressive clinical course characterized by selective growth of tumor cells within the vessels. Its pathogenesis is still uncertain and there is little information on the underlying genomic alterations. In this study, we performed a clinicopathologic and next-generation sequencing analysis of 15 cases of IVLBCL using a custom panel for the detection of alterations in 68 recurrently mutated genes in B-cell lymphomagenesis. Six patients had evidence of hemophagocytic syndrome. Four patients presented concomitantly a solid malignancy. Tumor cells outside the vessels were observed in 7 cases, 2 with an overt diffuse large B-cell cell lymphoma. In 4 samples, tumor cells infiltrated lymphatic vessel in addition to blood capillaries. Programmed death-ligand 1 (PD-L1) was positive in tumor cells in 4 of 11 evaluable samples and in macrophages intermingled with tumor cells in 8. PD-L1 copy number gains were identified in a higher proportion of cases expressing PD-L1 than in negative tumors. The most frequently mutated gene was PIM1 (9/15, 60%), followed by MYD88 L265P and CD79B (8/15, 53% each). In 6 cases, MYD88 L265P and CD79B mutations were detected concomitantly. We also identified recurrent mutations in IRF4, TMEM30A, BTG2, and ETV6 loci (4/15, 27% each) and novel driver mutations in NOTCH2, CCND3, and GNA13, and an IRF4 translocation in 1 case each. The mutational profile was similar in patients with and without evidence of hemophagocytic syndrome and in cases with or without dissemination of tumor cells outside the vessels. Our results confirm the relevance of mutations in B-cell receptor/nuclear factor-κB signaling and immune escape pathways in IVLBCL and identify novel driver alterations. The similar mutational profile in tumors with extravascular dissemination suggests that these cases may also be considered in the spectrum of IVLBCL.Keywords
This publication has 48 references indexed in Scilit:
- Intravascular large B-cell lymphoma presenting with fulminant pseudomembranous colitisPathology - Research and Practice, 2013
- Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomicsNature, 2012
- Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adultsBlood, 2011
- Oncogenically active MYD88 mutations in human lymphomaNature, 2010
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006
- Intravascular lymphoma: a neoplasm of ‘homeless’ lymphocytes?Hematological Oncology, 2006
- Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’1British Journal of Haematology, 2004
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004